Evidence map›Paper›PMID 36071738›Full record

ArticleThe mental health clinician2022

Perceptions and barriers of adverse drug reaction reporting within inpatient state psychiatric facilities.

Carolyn O'Donnell, Tammie Lee Demler, Charisse Dzierba

Abstract read
In one paragraph

Article in The mental health clinician, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Carolyn O'DonnellPharmacy Manager, The New York State Office of Mental Health at Buffalo Psychiatric Center, Buffalo, New York; Residency Program Director and Professor (adjunct), Department of Pharmacy Practice, State University of New York at Buffalo School of Pharmacy and Pharmaceutical Sciences, Buffalo, New York; Clinical Associate Professor, Department of Psychiatry, State University of New York at Buffalo School of Medicine, Buffalo, New York.ORCID https://orcid.org/0000-0001-7335-3286
Tammie Lee DemlerPharmacy Manager, The New York State Office of Mental Health at Buffalo Psychiatric Center, Buffalo, New York; Residency Program Director and Professor (adjunct), Department of Pharmacy Practice, State University of New York at Buffalo School of Pharmacy and Pharmaceutical Sciences, Buffalo, New York; Clinical Associate Professor, Department of Psychiatry, State University of New York at Buffalo School of Medicine, Buffalo, New York.ORCID https://orcid.org/0000-0002-3794-9610
Charisse DzierbaClinical Pharmacist, The New York State Office of Mental Health at Buffalo Psychiatric Center, Buffalo, New York.ORCID https://orcid.org/0000-0001-8495-3295

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Adverse drug reactions (ADRs) are a leading cause of morbidity and mortality for hospitalized patients. Health care organizations track ADRs to reduce patient mortality, reduce hospital readmissions, decrease costs, and improve patient care. Differing definitions of ADRs cause confusion among providers, leading to hesitation with ADR reporting. The objective of this study was to understand health care professionals' perspectives of ADR reporting within inpatient state psychiatric facilities. Methods: A survey was sent to 143 health care professionals throughout 25 inpatient state psychiatric facilities within 1 state. The survey assessed the definition of an ADR, confidence in reporting, barriers to reporting, the role of reporting, who should report and review ADRs, and strategies for process improvement. Results: The survey had a 75.5% response rate with 108 respondents. Most respondents could identify the definition of an ADR, were moderately confident in reporting ADRs, and understood the importance of ADR reporting. Barriers to ADR reporting included the reaction not being serious, a lack of information about the ADR, or not enough clarity on how to report an ADR. Fear of retaliation was an additional barrier to ADR reporting. Training and direction on ADR reporting, education on real versus perceived consequences, a designated point person to aid in reporting, and better access to reporting technology were suggested improvements for ADR reporting. Discussion: From this survey, it is evident that respondents believe improved education and training, improved communication regarding reporting consequences, and consensus on the definition of an ADR would encourage reporting.

Indexed as

adverse drug reactionsfear of retaliationreporting barriers

Identifiers

PMID36071738
PMCPMC9405632

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.